Tagged with M

Hong Kong Well established as Asia’s leading financial services and trading hub, Hong Kong is now looking to better position itself as a centre for biotechnology investment and start-ups. However, in a risk-averse investment environment with strong basic research but little tradition of translational science, such a transformation will take time, capital,…

Korea A roundup of some of the most important recent stories from the burgeoning South Korean pharma and biotech industry, including a government plan to expand collaboration with the global innovation hub in Boston, US; a list of some of the country’s most important biotech companies; and Medtronic’s move to purchase…

USA David H. Crean, Ph.D., Managing Partner at Cardiff Advisory, provides his insights on the potential impact of the US Federal Trade Commission (FTC)’s antitrust policies on biopharmaceutical mergers and acquisitions. Crean expects to see a continuation of 2023’s strong start to M&A and questions whether the FTC’s newly-aggressive approach will…

Belgium After almost 20 years with AbbVie, Renaud Decroix still feels as engaged and motivated as ever by the goal of having a remarkable impact on patients’ lives. Decroix highlights some of the access barriers currently standing in the way of achieving this vision in Belgium, the importance of building sustainable…

Hong Kong As managing director of the CR-CP Life Science Fund, whose shareholders, CR Group and CP Group, are on the Fortune Global 500 List, Da Liu leads investments in life sciences companies globally, especially those in emerging sectors such as RNA therapeutics and cancer screening. In conversation with PharmaBoardroom, Liu discusses…

Belgium Medaxes – the Belgian industry association for companies producing generic and biosimilar medicines, as well as other off-patent medicines and self-care products – welcomed a new CEO in 2022, Jasmien Coenen. Here, Coenen describes how the growing awareness of generics and biosimilars in Belgium is not yet translating into a…

Belgium Théa veteran and GM of the French ophthalmology midcap’s BeLux affiliate, Ivan Perrichon, reveals the company’s plans to pursue its growth trajectory, launch ten new products in Belgium and reach a local turnover of EUR 30 million over the next five years. He also discusses Théa’s plans to address progressive…

Hong Kong Tech entrepreneur and investor Duncan Chiu has long been committed to developing local technology and innovation in Hong Kong. He discusses the current blueprint for advancing life sciences, advanced manufacturing, AI, big data and FinTech in the region and the need for government involvement to incentivise investment.   Historically, we…

Belgium Belgium is a hugely significant country for GSK – which employs 9,000 people in the country – as host to three of the firm’s major vaccine sites, the global headquarters for its vaccines division, and many of its oncology and haematology clinical trials. Recently installed VP and GM BeLux Emmanuelle…

Belgium Paul Newton of Vertex Pharmaceuticals – one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry – outlines the company’s footprint in Benelux, how it is looking to take learnings from its success in cystic fibrosis treatment into new therapeutic areas,…

Brazil The latest pharma news from Brazil, including Daiichi Sankyo’s new plant; Bristol Myers Squibb’s re-entry into Brazil’s cardiology market; the Anvisa approval of HIV prevention drug, cabotegravir; Merck’s gamble on the Brazilian obesity market and Novo Nordisk’s patent extension denial.   Japan’s Daiichi Sankyo invests $80 million to expand Brazilian…

Belgium Thanks to its world-renowned networks of medical and academic institutions, the long-standing presence of Big Pharma, and a favourable regulatory environment, Belgium has a well-established tradition of excellence in clinical trials. Pharma industry leaders and Belgian government officials weigh in on the factors threatening the country’s position as a clinical…